<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01255813</url>
  </required_header>
  <id_info>
    <org_study_id>Pathway CH-1 (CIP-001)</org_study_id>
    <nct_id>NCT01255813</nct_id>
  </id_info>
  <brief_title>Sphenopalatine Ganglion Stimulation for the Acute Treatment of Cluster Headache</brief_title>
  <official_title>Sphenopalatine Ganglion Stimulation for the Acute Treatment of Cluster Headache</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Autonomic Technologies, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Autonomic Technologies, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the proposed clinical study is to evaluate the use of an implanted&#xD;
      Neurostimulator to provide Sphenopalatine Ganglion (SPG) stimulation for the management of&#xD;
      the pain associated with cluster headaches.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2010</start_date>
  <completion_date type="Actual">March 2013</completion_date>
  <primary_completion_date type="Actual">March 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of device related Serious Adverse Events (SAEs)</measure>
    <time_frame>Implant through the Experimental Period</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Acute Pain Relief response (as defined by patient)</measure>
    <time_frame>15 minutes</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pain Freedom</measure>
    <time_frame>15 minutes</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rescue medication use</measure>
    <time_frame>90 minutes</time_frame>
    <description>Use of medications to treat headache pain within 90 minutes after initiating therapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain Relief after initiating therapy</measure>
    <time_frame>30 minutes</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain Relief after initiating therapy</measure>
    <time_frame>60 minutes</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain Relief after initiating therapy</measure>
    <time_frame>90 minutes</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">43</enrollment>
  <condition>Chronic Cluster Headache</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Sub-perception</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Full Stimulation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Stimulation (Sub-perception)</intervention_name>
    <description>Stimulation applied below the perception threshold</description>
    <arm_group_label>Sub-perception</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Stimulation (Full)</intervention_name>
    <description>Stimulation applied above the perception threshold</description>
    <arm_group_label>Full Stimulation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Control</intervention_name>
    <description>No stimulation applied</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age from 18 to 65 years old (inclusive).&#xD;
&#xD;
          -  Subject has been diagnosed with chronic cluster headache according to the 2004&#xD;
             International Headache Society (IHS) criteria 3.1.2.&#xD;
&#xD;
          -  Subject reports a minimum of 4 cluster headaches per week.&#xD;
&#xD;
          -  Subject reports dissatisfaction with current cluster headache treatment (Criterion&#xD;
             includes both preventive or abortive therapy per the Investigator's standard of care.&#xD;
             Reasons for dissatisfaction with existing headache therapies may include failure of&#xD;
             therapies, contraindication, side effects of therapies, or patient refusal of&#xD;
             available therapies)&#xD;
&#xD;
          -  Subject is able to distinguish cluster headaches from other headaches (i.e.,&#xD;
             tension-type headaches).&#xD;
&#xD;
          -  Subject has the ability to read and comprehend, and to reliably record information as&#xD;
             required by the Protocol.&#xD;
&#xD;
          -  Subject is able to provide written informed consent prior to participation in the&#xD;
             study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subject has had a change in type or dosage of prophylactic headache medications &lt; one&#xD;
             (1) month prior to study enrollment&#xD;
&#xD;
          -  Subject has undergone facial surgery in the area of the pterygopalatine fossa or&#xD;
             zygomaticomaxillary buttress ipsilateral to the planned implant site within the last&#xD;
             four (4) months.&#xD;
&#xD;
          -  Subject has active oral or dental abscess.&#xD;
&#xD;
          -  Subject has been treated with radiation to the facial region within the last six (6)&#xD;
             months.&#xD;
&#xD;
          -  Subject has been diagnosed with any major infectious processes such as osteomyelitis,&#xD;
             or primary or secondary malignancies involving the face that have been active or&#xD;
             required treatment in the past six (6) months.&#xD;
&#xD;
          -  Subject has other significant pain problem that might confound the study assessments&#xD;
             in the opinion of the Investigator.&#xD;
&#xD;
          -  Subject is a woman of childbearing age who is pregnant, nursing, or not using&#xD;
             contraception.&#xD;
&#xD;
          -  Subject is currently participating or has participated in the last month in another&#xD;
             clinical study in which the subject has, is, or will be exposed to an investigational&#xD;
             or non-investigational drug or device.&#xD;
&#xD;
          -  Subject is felt to be at risk of non-compliance (e.g., for completing the diary or&#xD;
             maintaining a stable headache medicine regimen) in the Investigator's opinion.&#xD;
&#xD;
          -  Subject has had previous lesional radio-frequency ablation of the ipsilateral&#xD;
             sphenopalatine ganglion (SPG).&#xD;
&#xD;
          -  Subject has had blocks of the ipsilateral SPG in the last three (3) months.&#xD;
&#xD;
          -  Subject has undergone botulinum toxin injections of the head and/or neck in the last&#xD;
             three (3) months.&#xD;
&#xD;
          -  Subject has or requires a pacemaker/defibrillator or other implantable device having a&#xD;
             sense amplifier.&#xD;
&#xD;
          -  Subject has a history of bleeding disorders or coagulopathy or is unable to&#xD;
             discontinue anticoagulation, antiplatelet, or GP IIb IIIa inhibitor medication in&#xD;
             preparation for the implantation procedure.&#xD;
&#xD;
          -  Subject is not suitable for the study for any reason in the judgment of the&#xD;
             Investigator.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean Schoenen, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Professor of Functional Neuroanatomy, Leige University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Citadelle Hospital</name>
      <address>
        <city>Liege</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Danish Headache Center, Dept. of Neurology, Glostrup Hospital</name>
      <address>
        <city>Glostrup</city>
        <zip>2600</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Headache Center, Dept. of Neurology, University Duisburg-Essen</name>
      <address>
        <city>Essen</city>
        <zip>45147</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut fur systemische Neurowissenschaften, Universitastsklinikum Hamburg-Eppendorf (UKE)</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Neurology, University Clinic Hospital, University of Valencia</name>
      <address>
        <city>Valencia</city>
        <zip>46010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Denmark</country>
    <country>Germany</country>
    <country>Spain</country>
  </location_countries>
  <removed_countries>
    <country>France</country>
  </removed_countries>
  <verification_date>December 2015</verification_date>
  <study_first_submitted>December 3, 2010</study_first_submitted>
  <study_first_submitted_qc>December 6, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 7, 2010</study_first_posted>
  <last_update_submitted>December 28, 2015</last_update_submitted>
  <last_update_submitted_qc>December 28, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 29, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Chronic Cluster Headache</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cluster Headache</mesh_term>
    <mesh_term>Headache</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

